On the HCPLive ankylosing spondylitis page, resources on the topics of medical news and expert insight into the inflammatory disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on ankylosing spondylitis, and more.
March 31st 2023
Treatment with secukinumab was safe and effective for patients with ankylosing spondylitis and psoriatic arthritis, with significant reductions in disease activity scores observed through 52 weeks.
August 17th 2022
Increased Risk of Aortic Regurgitation, Atrial Fibrillation in Patients With Radiographic Axial SpondyloarthritisMay 4th 2022
The European Alliance of Associations for Rheumatology (EULAR) recommends screening and early management of cardiovascular disease in patients with radiographic axial spondyloarthritis.
Upadacitinib Shows Promise for Ankylosing Spondylitis in SELECT-AXIS 1November 14th 2019
Aileen Pangan, MD, executive medical director of Immunology with AbbVie, discusses the results of the SELECT-AXIS 1 trial and what it indicates about upadacitinib as a treatment for ankylosing spondylitis.
Janet Pope, MD: Rheumatoid Areas in Most Need of ResearchSeptember 27th 2019
While conferences and annual meetings are often the place clinicians are exposed to new data, there are often niche areas where they seek further guidance or information. Janet Pope, MD, discusses where she would like to see more research dedicated.
New Ankylosing Spondylitis, Axial Spondyloarthritis Guidelines ReleasedAugust 23rd 2019
A new set of guidelines has been released by the American College of Rheumatology, Spondylitis Association of America and the Spondyloarthritis Research and Treatment Network are offering guidance to physicians on treating axial spondyloarthritis.
Novartis Launches Head-to-head Clinical Trial for Secukinumab and BiosimilarJanuary 9th 2018
The trial is the first head-to-head clinical comparison in ankylosing spondylitis investigating the superiority of secukinumab for slowing spinal bone damage versus proposed biosimilar adalimumab.
Combination of TNFis and NSAIDs May Slow Ankylosing Spondylitis
Speaking at ACR 2016, the current chair of the Spondyloarthritis Research and Treatment Network (SPARTAN) presented data that showed that a combination of inflammatory drugs may inhibit ankylosis, the painful fusion of bones.
Long-Term Secukinumab Treatment Safe and Effective for Patients with Psoriatic Arthritis
Patients with active psoriatic arthritis treated with secukinumab for 2 years in the FUTURE-1 trial experienced sustained decreases in disease activity and symptoms, leading to improvements in physical function and quality of life.